Aug 5, 2026 08:00PM
Jun 24, 2026 08:00PM
Jun 24, 2026 08:00PM
Jun 24, 2026 07:01AM
Jun 24, 2026 07:00AM
Jun 21, 2026 08:00PM
Jun 21, 2026 08:00PM Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
May 31, 2026 08:00PM
May 31, 2026 08:00PM
May 21, 2026 07:49PM
May 21, 2026 07:49PM
May 21, 2026 07:49PM
May 10, 2026 08:00PM
Mar 1, 2026 07:00PM Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jan 26, 2026 07:00PM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Sep 18, 2025 12:00AM
Sep 17, 2025 06:30AM Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
Sep 7, 2025 08:30PM
Sep 7, 2025 08:30PM
Aug 27, 2025 06:08AM
Aug 24, 2025 08:00PM
Aug 24, 2025 08:00PM
Aug 4, 2025 08:00PM
Aug 4, 2025 08:00PM Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
Jul 23, 2025 10:36AM
Jul 16, 2025 08:00PM
Jul 16, 2025 08:00PM
Jul 16, 2025 08:00PM
Jun 30, 2025 12:04AM
Jun 15, 2025 08:00PM
Jun 4, 2025 08:23PM Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
Jun 3, 2025 08:00PM
Jun 2, 2025 09:00PM
Jun 1, 2025 08:00PM
May 31, 2025 09:39PM
Mar 30, 2025 09:19PM
Mar 26, 2025 06:21AM
Mar 18, 2025 08:57PM Innovent and HUTCHMED Say FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint
Mar 18, 2025 08:55PM
Mar 2, 2025 07:00PM
Feb 16, 2025 07:00PM
Jan 15, 2025 07:00PM
Jan 2, 2025 07:00PM
Dec 20, 2024 07:10AM
Dec 15, 2024 06:57PM Innovent and Eli Lilly Expand Collaboration
Dec 15, 2024 06:55PM

328,149 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All